Boston Scientific, Guidant Close The Deal Following FTC Approval
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
You may also be interested in...
Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
Boston Sci, J&J Bury The Hatchet In Guidant Acquisition Dispute
Boston Scientific will pay Johnson & Johnson $600 million to settle allegations that cardiovascular device firm Guidant breached a merger agreement with J&J in 2006, a far cry from the $7 billion sought by J&J
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA